Table 1 Characteristics of anti-periplakin IgG and IgE –positive and –negative patients
Total (n = 260) | IgG PPL + (n = 47) | IgG PPL– (n = 213) | P value | Total (n = 138) | IgE PPL + (n = 12) | IgE PPL– (n = 126) | P value | |
|---|---|---|---|---|---|---|---|---|
Male | 80 (30.8 %) | 20 (42.6 %) | 60 (28.2 %) | 0.053 | 44 (31.9 %) | 6 (50.0 %) | 38 (30.2 %) | 0.19 |
Age (yr) | 48.5 (14.2) | 47.5 (13.4) | 48.7 (14.4) | 0.59 | 49.5 (15.1) | 47.1 (16.3) | 49.7 (15.0) | 0.57 |
Asthma severity | 0.89 | 0.67 | ||||||
Mild | 35 (13.4 %) | 6 (12.7 %) | 29 (13.6 %) | 16 (11.6 %) | 2 (16.6 %) | 14 (11.1 %) | ||
Moderate | 37 (14.2 %) | 8 (17.0 %) | 29 (13.6 %) | 16 (11.6 %) | 1 (8.3 %) | 15 (11.9 %) | ||
Severe | 188 (72.3 %) | 33 (70.2 %) | 155(72.8 %) | 106(76.8 %) | 9 (75.0 %) | 97 (77.0 %) | ||
Atopy | 162 (69.8 %) | 34 (77.3 %) | 128(68.1 %) | 0.23 | 95 (72.0 %) | 10 (83.3 %) | 85 (70.8 %) | 0.5 |
BMI | 26.9 (5.6) | 26.9 (5.7) | 27.0 (5.6) | 0.91 | 27.5 (5.3) | 25.4 (3.0) | 27.7 (5.4) | 0.14 |
Asthma duration (yr) | 23.2 [9.1–35.9] | 28.4 [14.5–37.7] | 21.1 [8.0–35.7] | 0.28 | 21.5 [8.2–36.4] | 13.6 [8.0–31.7] | 23.0 [8.8–36.4] | 0.31 |
FEV1 (% predicted) | 81.0 (23.4) | 84.1 (20.8) | 80.4 (23.9) | 0.32 | 78.7 (24.8) | 87.8 (28.2) | 77.8 (24.4) | 0.18 |
FEV1/FVC (%) | 68.6 (14.4) | 68.3 (15.6) | 68.7 (14.2) | 0.88 | 66.5 (15.3) | 65.3 (15.0) | 66.7 (15.4) | 0.77 |
Total IgE (kUI/l) | 424.0 (643.5) | 446.6 (826.7) | 418.6 (593.9) | 0.45 | 425.0 (665.5) | 318.2 (377.9) | 436.1 (688.8) | 0.82 |
Blood eosinophils (/mm3) | 305.4 (278.8) | 322.3 (185.1) | 301.4 (297.1) | 0.06 | 316.5 (251.7) | 378.9 (248.0) | 310.7 (252.2) | 0.32 |
Nasal polyposis | 51 (19.9 %) | 13 (27.7 %) | 38 (18.2 %) | 0.14 | 27 (19.6 %) | 6 (50.0 %) | 21 (16.7 %) | 0.01 |
Smoker or former smoker | 100 (38.6 %) | 22 (46.8 %) | 78 (36.8 %) | 0.26 | 56 (38.6 %) | 4 (33.3 %) | 52 (41.2 %) | 0.8 |
Occupational asthma | 32 (12.4 %) | 9 (19.1 %) | 23 (10.9 %) | 0.12 | 18 (13.1 %) | 1 (8.3 %) | 17 (13.6 %) | 1 |
GERD | 103(39.6 %) | 19 (40.4 %) | 84 (39.4 %) | 0.9 | 58 (42.0 %) | 4 (33.3 %) | 54 (42.9 %) | 0.52 |
Asthma control | ||||||||
well-controlled | 78 (30.2 %) | 17 (36.2 %) | 61 (28.9 %) | 0.61 | 38 (27.7 %) | 4 (33.3 %) | 34 (27.2 %) | 0.92 |
partly controlled | 76 (29.5 %) | 13 (27.7 %) | 63 (29.9 %) | 36 (26.3 %) | 3 (25.0 %) | 33 (26.4 %) | ||
uncontrolled | 104(40.3 %) | 17 (36.2 %) | 87 (41.2 %) | 63 (46.0 %) | 5 (41.7 %) | 58 (46.4 %) | ||
JUNIPER score | 10.2 (7.3) | 9.1 (8.1) | 10.5 (7.0) | 0.29 | 10.4 (7.3) | 6.1 (8.4) | 10.8 (7.1) | 0.08 |
At least 1 exacerbation in the previous year | 147 (58.8 %) | 22 (48.9 %) | 125 (61.0 %) | 0.13 | 81 (60.4 %) | 8 (72.7 %) | 73 (59.3 %) | 0.52 |
No. of oral steroid bursts in the previous year | 4.0 [2.0–8.0] | 3.0 [2.0–4.5] | 4.0 [2.0–8.0] | 0.39 | 4.0 [2.0–8.0] | 3.5 [2.0–4.0] | 5.0 [2.0–8.0] | 0.38 |
Inhaled steroids | 223 (85.8 %) | 42 (89.4 %) | 181 (85.0 %) | 0.43 | 123 (89.1 %) | 10 (83.3 %) | 113 (89.7 %) | 0.62 |
Daily dose of inhaled steroids (μg/d) | 1781.1 (1154.1) | 1463.5 (1113.6) | 1854.8 (1153.8) | 0.01 | 1801.8 (1092.8) | 1700.0 (1032.8) | 1810.8 (1101.9) | 0.86 |
Daily oral steroids | 47 (18.1 %) | 7 (14.9 %) | 40 (18.9 %) | 0.52 | 25 (18.2 %) | 2 (16.7 %) | 23 (18.4 %) | 1 |
Omalizumab | 15 (5.8 %) | 2 (4.3 %) | 13 (6.2 %) | 1 | 8 (5.8 %) | 0 (0.0 %) | 8 (6.3 %) | 0.36 |